Paratek Pharmaceuticals is a biopharmaceutical company based in San Francisco, CA, dedicated to addressing the critical concern of antimicrobial resistance (AMR) for public health and national security. They develop and commercialize innovative treatment options, such as their FDA-approved tetracycline-class antibiotic NUZYRA, to combat complex medical issues caused by susceptible bacteria, including community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
With a disciplined team of groundbreaking innovators, Paratek is committed to saving lives by providing the right drugs, knowledge, and people to transform everyday decisions into everyday triumphs. Their efforts to combat AMR involve responsible antibiotic use, improved surveillance, research into new antibiotics, and policy changes to enable a vibrant marketplace that recognizes the life-saving value of novel antibiotics.
Generated from the website